Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Nalbuphine hydrochloride ER by Trevi Therapeutics for Prurigo: Likelihood of Approval
Nalbuphine hydrochloride ER is under clinical development by Trevi Therapeutics and currently in Phase III for Prurigo. According to GlobalData,...